Baader Bank Aktiengesellschaft Sells 2,965 Shares of Stryker Corporation $SYK

Baader Bank Aktiengesellschaft lessened its position in shares of Stryker Corporation (NYSE:SYK) by 15.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 16,130 shares of the medical technology company’s stock after selling 2,965 shares during the period. Baader Bank Aktiengesellschaft’s holdings in Stryker were worth $5,287,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Burling Wealth Partners LLC increased its holdings in Stryker by 15.4% in the 1st quarter. Burling Wealth Partners LLC now owns 14,419 shares of the medical technology company’s stock worth $4,738,000 after acquiring an additional 1,920 shares during the last quarter. Andra AP fonden raised its stake in Stryker by 30.2% in the 1st quarter. Andra AP fonden now owns 65,055 shares of the medical technology company’s stock valued at $21,376,000 after acquiring an additional 15,095 shares during the period. Long Road Investment Counsel LLC lifted its holdings in Stryker by 0.9% during the first quarter. Long Road Investment Counsel LLC now owns 42,957 shares of the medical technology company’s stock valued at $14,115,000 after purchasing an additional 401 shares during the last quarter. Johnson Financial Group Inc. lifted its holdings in Stryker by 123.9% during the first quarter. Johnson Financial Group Inc. now owns 2,803 shares of the medical technology company’s stock valued at $924,000 after purchasing an additional 1,551 shares during the last quarter. Finally, AlTi Global Inc. boosted its position in Stryker by 124.9% during the first quarter. AlTi Global Inc. now owns 2,085 shares of the medical technology company’s stock worth $687,000 after purchasing an additional 1,158 shares during the period. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

NYSE SYK opened at $318.80 on Tuesday. The company’s 50 day simple moving average is $313.41 and its two-hundred day simple moving average is $336.46. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $404.87. The stock has a market capitalization of $122.22 billion, a PE ratio of 36.90, a P/E/G ratio of 2.05 and a beta of 0.77.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter last year, the firm earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts predict that Stryker Corporation will post 14.99 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s payout ratio is presently 40.74%.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares in the company, valued at $601,005,282.40. This represents a 13.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 323,264 shares of company stock worth $100,659,489 over the last ninety days. 4.60% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on SYK shares. Truist Financial reiterated a “hold” rating and issued a $330.00 target price (down from $380.00) on shares of Stryker in a research note on Monday, May 4th. Sanford C. Bernstein set a $410.00 price target on shares of Stryker in a research note on Friday, May 1st. Leerink Partners cut their price objective on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a report on Friday, June 5th. Argus set a $370.00 price target on Stryker in a research report on Thursday, July 9th. Finally, Deutsche Bank Aktiengesellschaft set a $315.00 target price on Stryker in a research note on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $392.52.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.